Evidence map›Paper›PMID 41711155›Full record

ArticleGenes, chromosomes & cancer2026

Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.

Kathleen Varty, Leah MacLean, Doha Itani, Monowar Hossain, Cenk Acar, James Michael, Trisha Daigle-Maloney, Robert Thompson, Brian Johnston, Crispin Russell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, chromosomes & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kathleen VartyDepartment of Biological Sciences, University of New Brunswick, Saint John, New Brunswick, Canada.ORCID 0000-0003-0539-3168
Leah MacLeanBeatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada.
Doha ItaniDepartment of Pathology, Dalhousie University, Saint John, New Brunswick, Canada.
Monowar HossainDepartment of Pathology, Dalhousie University, Saint John, New Brunswick, Canada.
Cenk AcarDepartment of Pathology, Dalhousie University, Saint John, New Brunswick, Canada.
James MichaelDepartment of Medicine, Dalhousie University, Saint John, New Brunswick, Canada.
Trisha Daigle-MaloneyDepartment of Oncology, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
Robert ThompsonDepartment of Oncology, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
Brian JohnstonDivision of Thoracic Surgery, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
Crispin RussellDivision of Thoracic Surgery, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
Jeanette E BoudreauBeatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada.
Daniel GastonBeatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada.
Tony ReimanDepartment of Biological Sciences, University of New Brunswick, Saint John, New Brunswick, Canada.ORCID 0000-0002-2706-8764

Funding

Beatrice Hunter Cancer Research InstituteCanadian Cancer Society'sTerry Fox Research Institute and Canadian Institutes of Health Research
6 · The paper itself

Abstract

introductionNext-generation sequencing (NGS) is routinely used for lung cancer genomic profiling to identify known, actionable, non-synonymous driver mutations. Recent findings suggest that synonymous variants may also be cancer drivers. MATERIALS AND

methodsWe analyzed genomic data and clinical outcomes for patients (n = 353) with non-small cell lung cancer (NSCLC) sequenced with the Oncomine Focus 52-gene NGS panel (ThermoFisher Scientific, Waltham, MA, USA) at the Saint John Regional Hospital in New Brunswick, Canada, from January 2019 to January 2023.

resultsKRAS was the most commonly mutated gene in this cohort from Saint John, New Brunswick, with a higher prevalence than reported in other populations. Several novel synonymous variants were identified, including in ALK, EGFR, FGFR2, FGFR3, MYC, NF1, NRAS, and PIK3CA, with potential effects on MAPK/ERK and PI3K/AKT signaling.

conclusionThis cohort demonstrates both expected and distinct genomic features, including novel synonymous variants in oncogenic pathways. These findings suggest regional variation in NSCLC genomics and support further study of synonymous variants in disease progression.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)

Identifiers

PMID41711155
PMCPMC12917934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.